Attenuated transforming growth factor (3 signaling promotes nuclear factor-κB activation in head and neck cancer

Cancer Research

Volumn 69, Issue 8, 2009, Pages 3415-3424

  Cohen, Jonah ^a   Chen, Zhong ^a   Lu, Shi Long ^b   Yang, Xin Ping ^a   Aran, Pattatheyil ^a   Ehsanian, Reza ^a   Brown, Matthew S ^a   Lu, Hai ^a   Yan, Bin ^a   Diallo, Oumou ^a   Wang, Xiao Jing ^b   Waes, Carter Van ^a,c  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSFECTION; GENOTYPE; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; KNOCKOUT MOUSE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; GENE DELETION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; MICE; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; PROTEOGLYCANS; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC; TRANSFORMING GROWTH FACTOR BETA; TUMOR SUPPRESSOR PROTEIN P53;

EID: 65949113847     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-3704     Document Type: Article

References (47)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70. (Pubitemid 30046295)
2. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006; 441: 431-6. (Pubitemid 44050137)
3. Perkins ND. Integrating cell-signalling pathways with NF-κB and IKK function. Nat. Rev. Mol. Cell Biol. 2007; 8: 49-62. (Pubitemid 46012014)
4. Van Waes C. Nuclear factor-κB in development, prevention, and therapy of cancer. Clin. Cancer Res 2007; 13: 1076-82. (Pubitemid 46424045)
5. Brown M, Cohen J, Arun P, Chen Z, Van Waes C. NF-κB in carcinoma therapy and prevention. Expert Opin Ther. Targets 2008; 12: 1109-22.
6. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001; 29: 117-29. (Pubitemid 32952643)
7. Markowitz SD, Roberts AB. Tumor suppressor activity of the TGP-β pathway in human cancers. Cytokine Growth Factor Rev 1996; 7: 93-102. (Pubitemid 27202668)
8. Wang D, Song H, Evans JA, Lang JC, Schuller DE, Weghorst CM. Mutation and down-regulation of the transforming growth factor β type II receptor gene in primary squamous cell carcinomas of the head and neck. Carcinogenesis 1997; 18: 2285-90. (Pubitemid 28134761)
9. Huntley SP, Davies M, Matthews JB. et al. Attenuated type II TGF-β receptor signalling in human malignant oral keratinocytes induces a less differentiated and more aggressive phenotype that is associated with metastatic dissemination. Int J. Cancer 2004; 110: 170-6. (Pubitemid 38580386)
10. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J. Med 2001; 345: 1890-900. (Pubitemid 33716564)
11. Taylor D, Koch WM, Zahurak M, Shah K, Sidransky D, Westra WH. Immunohistoehemieal detection of p53 protein accumulation in head and neck cancer: correlation with p53 gene alterations. Hum Pathol 1999; 30: 1221-5. (Pubitemid 29480892)
12. Friedman J, Nottingham L, Duggal P. et al. Deficient TP53 expression, function, and cisplatin sensitivity are restored by quinacrine in head and neck cancer. Clin. Cancer Res 2007; 13: 6568-78. (Pubitemid 350206790)
13. Boyle JO, Hakim J, Koch W. et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53: 4477-80. (Pubitemid 23304366)
14. Yan B, Chen G, Saigal K. et al. Systems biology-defined NF-κB regulons, interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p53 status. Genome Biol. 2008; 9: R53.
15. Yan B, Yang X, Lee TL. et al. Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-κB and other signal transcription factors in head and neck squamous cell carcinoma. Genome Biol. 2007; 8: R78.
16. Lu SL, Herrington H, Reh D. et al. Loss of transforming growth factor-β type II receptor promotes metastatic head-and-neck squamous cell carcinoma. Genes Dev 2006; 20: 1331-42. (Pubitemid 43727593)
17. Lee TL, Yeh J, Friedman J. et al. A signal network involving coactivated NF-κB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J. Cancer 2008; 122: 1987-98.
18. Richtsmeier WJ, Carey TE. Rationalized nomenclature for head and neck carcinomas. Arch Otolaryngol Head Neck Surg 1987; 113: 1339-40.
19. Yuen HF, Chan YP, Chan KK. et al. Id-1 and Id-2 are markers for metastasis and prognosis in oesophageal squamous cell carcinoma. Br J. Cancer 2007; 97: 1409-15. (Pubitemid 350114787)
20. Lee H, Arsura M, Wu M, Duyao M, Buckler AJ, Sonenshein GE. Role of Rel-related factors in control of e-mye gene transcription in receptor-mediated apopto-sis of the murine B cell WEHI 231 line. J. Exp Med 1995; 181: 1169-77.
21. Esrig D, Spruck CH, Nichols PW. et al. p53 nuclear protein accumulation correlates with mutations in the p53 gene, tumor grade, and stage in bladder cancer. Am J. Pathol 1993; 143: 1389-97. (Pubitemid 24057109)
22. Campbell KJ, Perkins ND. Reprogramming RelA. Cell Cycle 2004; 3: 869-72. (Pubitemid 40179462)
23. Cavin LG, Romieu-Mourez R, Panta GR. et al. Inhibition of CK2 activity by TGF-β1 promotes IκB-α protein stabilization and apoptosis of immortalized hepatocytes. Hepatology 2003; 38: 1540-51. (Pubitemid 37466980)
24. Lam LT, Davis RE, Pierce J. et al. Small molecule inhibitors of IkB kinase are selectively toxic for subgroups of diffuse large B-cell lymphomas defined by gene expression profiling. Clin. Cancer Res 2003; 11: 28-40.
25. Chung CH, Parker JS, Ely K. et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-KB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 2006; 66: 8210-8. (Pubitemid 44299189)
26. Loukinova E, Dong G, Enamorado-Ayalya I. et al. Growth regulated oncogene-α expression by murine squamous cell carcinoma promotes tumor growth, metastasis, leukocyte infiltration and angiogenesis by a host CXC receptor-2 dependent mechanism. Oncogene 2000; 19: 3477-86. (Pubitemid 30487445)
27. Allen C, Duffy S, Teknos T. et al. Nuclear factor-κB-related serum factors as longitudinal biomarkers of response and survival in advanced oropharyngeal carcinoma. Clin. Cancer Res 2007; 13: 3182-90. (Pubitemid 46944900)
28. Fukai Y, Fukuchi M, Masuda N. et al. Reduced expression of transforming growth factor-β receptors is an unfavorable prognostic factor in human esophageal squamous cell carcinoma. Int J. Cancer 2003; 104: 161-6. (Pubitemid 36249790)
29. Turley RS, Finger EC, Hempel N, How T, Fields TA, Blobe GC. The type III transforming growth factor-β receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res 2007; 67: 1090-8. (Pubitemid 46270765)
30. Wyllie FS, Dawson T, Bond JA. et al. Correlated abnormalities of transforming growth factor-β1 response and p53 expression in thyroid epithelial cell transformation. Mol. Cell Endocrinol. 1991; 76: 13-21.
31. Reiss M, Munoz-Antonia T, Cowan JM, Wilkins PC, Zhou ZL, Vellucci VF. Resistance of human squamous carcinoma cells to transforming growth factor β1 is a recessive trait. Proc. Natl. Acad. Sci. U S A 1993; 90: 6280-4. (Pubitemid 23191499)
32. Reiss M, Vellucci VF, Zhou ZL. Mutant p53 tumor suppressor gene causes resistance to transforming growth factor β1 in murine keratinocytes. Cancer Res 1993; 53: 899-904. (Pubitemid 23077881)
33. Loukinova E, Chen Z, Van Waes C, Dong G. Expression of proangiogenic chemokine Gro 1 in low and high metastatic variants of Pam murine squamous cell carcinoma is differentially regulated by IL-1α, EGF and TGF-β1 through NF-κB dependent and independent mechanisms. Int J. Cancer 2001; 94: 637-44. (Pubitemid 33035682)
34. Loercher A, Lee TL, Ricker JL. et al. Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004; 64: 6511-23. (Pubitemid 39297908)
35. Kalo E, Buganim Y, Shapira KE. et al. Mutant p53 attenuates the SMAD-dependent transforming growth factor β1 (TGF-β1} signaling pathway by repressing the expression of TGF-β receptor type II. Mol. Cell Biol. 2007; 27: 8228-42. (Pubitemid 350234236)
36. Monteleone G, Mann J, Monteleone I. et al. A failure of transforming growth factor-β1 negative regulation maintains sustained NF-κB activation in gut inflammation. J. Biol. Chem 2004; 279: 3925-32. (Pubitemid 38198975)
37. Wang W, Huang XR, Li AG. et al. Signaling mechanism of TGF-β1 in prevention of renal inflammation: role of Smad7. J. Am Soc Nephrol 2005; 16: 1371-83. (Pubitemid 41716521)
38. Yu M, Yeh J, Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-κB kinase and aberrant nuclear factor-κB activation by serum factor (s) in head and neck squamous carcinoma cells. Cancer Res 2006; 66: 6722-31. (Pubitemid 44085630)
39. Duffey DC, Crowl-Bancroft CV, Chen Z. et al. Inhibition of transcription factor nuclear factor-κB by a mutant inhibitor-κBβ attenuates resistance of human head and neck squamous cell carcinoma to TNF-α caspase-mediated cell death. Br J. Cancer 2000; 83: 1367-74.
40. Bancroft CC, Chen Z, Yeh J. et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J. Cancer 2002; 99: 538-48. (Pubitemid 34461606)
41. Yeung KC, Rose DW, Dhillon AS. et al. Raf kinase inhibitor protein interacts with NF-κB-inducing kinase and TAK1 and inhibits NF-κB activation. Mol. Cell Biol. 2001; 21: 7207-17. (Pubitemid 32953475)
42. Li B, Cheung PY, Wang X. et al. Id-1 activation of PI3K/Akt/NFκB signaling pathway and its significance in promoting survival of esophageal cancer cells. Carcinogenesis 2007; 28: 2313-20. (Pubitemid 350111589)
43. Helbig G, Christopherson KW, Bhat-Nakshatri P. et al. NF-κB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J. Biol. Chem 2003; 278: 21631-8. (Pubitemid 36792563)
44. Young MR, Lathers DM. Myeloid progenitor cells mediate immune suppression in patients with head and neck cancers. Int J. Immunopharmacol 1999; 21: 241-52. (Pubitemid 29241776)
45. Young MR, Petruzzelli GJ, Kolesiak K, Achille N, Lathers DM, Gabrilovich DI. Human squamous cell carcinomas of the head and neck chemoattract immune suppressive CD34 (+) progenitor cells. Hum Immunol 2001; 62: 332-41. (Pubitemid 32298975)
46. Yang L, Huang J, Ren X. et al. Abrogation of TGFβ signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis. Cancer Cell 2008; 13: 23-35. (Pubitemid 350309741)
47. Xu W, Neckers L. Targeting the molecular chaperone heat shock protein 90 provides a multifaceted effect on diverse cell signaling pathways of cancer cells. Clin. Cancer Res 2007; 13: 1625-9. (Pubitemid 46952925)